RxDoctor Payments Data

Stephany Wims

Nurse Practitioner · Tacoma, WANPI 1083106645

Payments from drug & device makers

$641in general payments, 2019–2025

Across 24 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$129
  • Boehringer Ingelheim$124
  • AbbVie$78
  • Amgen$68
  • GSK$55
  • Biohaven Pharmaceuticals, Inc.$40
  • plus $147 from 6 others

What the payments were for

  • Food & beverage$641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641 in reported general payments places this provider in the 85th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$55,109
Medicare patients
209
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$81,567
RybelsusSemaglutide35$50,151
JardianceEmpagliflozin30$39,849
EliquisApixaban23$33,991
MounjaroTirzepatide18$24,549
MyrbetriqMirabegron24$20,136
TrulicityDulaglutide11$17,130
Combivent RespimatIpratropium/Albuterol Sulfate14$6,809
Varenicline Tartrate19$5,157
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,832
Albuterol Sulfate HfaAlbuterol Sulfate77$2,577
Gabapentin130$2,503
Atorvastatin Calcium229$2,413
Pregabalin64$1,959
Duloxetine Hcl85$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$18$131,71896 claims
Boehringer IngelheimJardiance, Combivent Respimat$124$46,65844 claims
PfizerEliquis$17$33,99123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →